In a combined diabetes/atherosclerosis mouse model, PPARγ agonists were found to exert antiatherogenic effects independent of a reduction in insulin resistance and plasma glucose [82], indicating that attenuation of insulin resistance is not the only mechanism through which PPARγ functions as an antiatherognic agent. The gene discussed is PPARG; the disease is diabetes mellitus.